GlassScriptPhysician profile
Timothy A Pham
NPI 1457549826
$7,405.91
in general payments reported to CMS, 2019-2025
24 companies · $841 in 2025
The $841 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $379 · 2020: $909 · 2021: $1,090 · 2022: $1,110 · 2023: $1,733 · 2024: $1,343 · 2025: $841.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,918.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,917.60 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $1,423.95 | 2019-2025 | Dupixent |
| Incyte Corporation | $1,007.44 | 2021-2024 | Opzelura |
| Genzyme Corporation | $959.14 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $833.86 | 2019-2024 | Airsupra, Fasenra |
| Glaxosmithkline, LLC. | $608.51 | 2020-2025 | Trelegy Ellipta, Arexvy, Nucala |
| Leo Pharma INC. | $551.00 | 2023-2025 | Adbry, Anzupgo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $351.54 | 2020-2024 | Spiriva Respimat |
| Takeda Pharmaceuticals U.S.A., INC. | $293.10 | 2020-2022 | |
| Optinose US, INC. | $210.37 | 2019-2024 | |
| Pfizer INC. | $186.77 | 2019-2024 | |
| Galderma Laboratories, L.P. | $137.99 | 2025 | Nemluvio |
| Kaleo, INC. | $133.07 | 2020-2024 | Auvi-Q |
| Hikma Pharmaceuticals USA | $111.16 | 2023 | Ryaltris |
| Teva Pharmaceuticals USA, INC. | $100.76 | 2019-2021 | |
| Sanofi-Aventis U.S. LLC | $98.99 | 2022 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Covis Pharma Gmbh | $98.92 | 2020-2021 | |
| Amgen INC. | $64.92 | 2021-2024 | Tezspire |
| Aimmune Therapeutics, INC. | $44.95 | 2020-2022 | |
| Uswm, LLC | $42.73 | 2021 | |
| Blueprint Medicines Corporation | $41.98 | 2022-2023 | Ayvakit |
| Genentech USA, INC. | $34.55 | 2021-2022 | |
| Phadia US INC. | $33.65 | 2021 | |
| Csl Behring | $21.55 | 2023 | Hizentra |
| Grifols USA, LLC | $15.01 | 2025 | Xembify |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Timothy Pham listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.